WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 528315
Description: Oxeglitazar, also known as EMD-336340 and LM-4156, is a peroxisome proliferator-activated receptor (PPAR) agonist potentially for the treatment of gout and type two diabetes.
MedKoo Cat#: 528315
Chemical Formula: C19H22O4
Exact Mass: 314.1518
Molecular Weight: 314.381
Elemental Analysis: C, 72.59; H, 7.05; O, 20.36
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Oxeglitazar; EMD-336340; EMD336340; EMD 336340; LM-4156; LM 4156; LM4156
IUPAC/Chemical Name: (2E,4E)-5-(7-methoxy-3,3-dimethyl-2,3-dihydrobenzo[b]oxepin-5-yl)-3-methylpenta-2,4-dienoic acid
InChi Key: FVGXANXBVWECQE-BYWGDBCOSA-N
InChi Code: InChI=1S/C19H22O4/c1-13(9-18(20)21)5-6-14-11-19(2,3)12-23-17-8-7-15(22-4)10-16(14)17/h5-11H,12H2,1-4H3,(H,20,21)/b6-5+,13-9+
SMILES Code: O=C(O)/C=C(C)/C=C/C1=CC(C)(C)COC2=CC=C(OC)C=C12
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 314.381 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Kalivoda A, Fischbach M, Kleinebudde P. Application of mixtures of polymeric carriers for dissolution enhancement of oxeglitazar using hot-melt extrusion. Int J Pharm. 2012 Dec 15;439(1-2):145-56. doi: 10.1016/j.ijpharm.2012.10.013. PubMed PMID: 23073606.
2: Badens E, Majerik V, Horváth G, Szokonya L, Bosc N, Teillaud E, Charbit G. Comparison of solid dispersions produced by supercritical antisolvent and spray-freezing technologies. Int J Pharm. 2009 Jul 30;377(1-2):25-34. doi: 10.1016/j.ijpharm.2009.04.047. PubMed PMID: 19442711.
3: Majerik V, Horváth G, Szokonya L, Charbit G, Badens E, Bosc N, Teillaud E. Supercritical antisolvent versus coevaporation: preparation and characterization of solid dispersions. Drug Dev Ind Pharm. 2007 Sep;33(9):975-83. PubMed PMID: 17891584.